Himanshu Shah, an activist investor and enormous shareholder of Novavax, whose inventory has plummeted over time, believes the corporate ought to reduce prices extra aggressively, scale back the dimensions of its board, and do extra to prop up its monetary efficiency. However are the criticisms legitimate?
The publish Is Shah Capital’s Criticism of Novavax Honest? A Wall Road Analyst Weighs In appeared first on MedCity Information.